Back to Search
Start Over
Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature.
- Source :
- Gut & Liver; Jan2014, Vol. 8 Issue 1, p109-112, 4p, 2 Diagrams, 1 Chart
- Publication Year :
- 2014
-
Abstract
- Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea. [ABSTRACT FROM AUTHOR]
- Subjects :
- HEMOLYTIC anemia
THROMBOCYTOPENIA
INFECTION
PANCREATIC cancer
CANCER patients
Subjects
Details
- Language :
- English
- ISSN :
- 19762283
- Volume :
- 8
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Gut & Liver
- Publication Type :
- Academic Journal
- Accession number :
- 93875233
- Full Text :
- https://doi.org/10.5009/gnl.2014.8.1.109